Shares of METiS TechBio surged 173 per cent on their Hong Kong debut on Wednesday as the AI-driven drug design start-up’s initial public offering drew strong demand from investors amid buoyant sentiment for AI-related stocks in the city.Its stocks first traded at HK$28.68, significantly higher than its offering price of HK$10.50 each.Co-founder and CEO of METiS TechBio, Lai Tsai-Ta, who obtained a PhD from the Massachusetts Institute of Technology in the US, said artificial intelligence had shortened drug development from years to just 18 months, said
SRCSouth China Morning Post
LANGEN
LEANCenter-Right
WORDS86
ENT5
WED · 2026-05-13 · 01:30 GMTBRIEF NSR-2026-0513-75760
NSR-2026-0513-75760News Report·EN·Technology
Hong Kong-listed biotech firm uses AI to produce nano-rockets to deliver life-saving drugs
Hong Kong-listed biotech firm METiS TechBio saw its shares surge 173% on its debut Wednesday, driven by strong investor interest in AI-related stocks. The company utilizes artificial intelligence to design and produce nano-rockets for drug delivery.
Julie ZhangSouth China Morning PostFiled 2026-05-13 · 01:30 GMTLean · Center-RightRead · 1 min
South China Morning PostFIG 01
Reading time
1min
Word count
86words
Sources cited
1cited
Entities identified
5entities
Quality score
100%
§ 01
Briefing Summary
AI-generatedNEWSAR · AI
Hong Kong-listed biotech firm METiS TechBio saw its shares surge 173% on its debut Wednesday, driven by strong investor interest in AI-related stocks. The company utilizes artificial intelligence to design and produce nano-rockets for drug delivery. METiS TechBio's co-founder and CEO stated that AI has significantly accelerated their drug development process, reducing it from years to approximately 18 months. This successful IPO highlights the growing investor confidence in AI-driven innovation within the biotechnology sector in Hong Kong.
Confidence 0.85Sources 1Claims 4Entities 5
§ 02
Article analysis
Model · rule-basedFraming
Technology
Economic Impact
Tone
Mixed Tone
AI-assessed
CalmNeutralAlarmist
Factuality
0.80 / 1.00
Factual
LowHigh
Sources cited
1
Limited
FewMany
§ 03
Key claims
4 extracted01
Artificial intelligence has shortened drug development from years to 18 months.
quoteLai Tsai-Ta
Confidence
1.00
02
METiS TechBio is an AI-driven drug design start-up.
factual
Confidence
1.00
03
METiS TechBio's shares surged 173% on their Hong Kong debut.
statistic
Confidence
1.00
04
METiS TechBio uses AI to produce nano-rockets for drug delivery.
factual
Confidence
0.90
§ 04
Full report
1 min read · 86 words§ 05
Entities
5 identifiedKey playerOppositionContextPositiveNeutralNegative
Organizations2
§ 06
Keywords & salience
7 termsai-driven drug design
1.00
nano-rockets
0.90
life-saving drugs
0.80
metis techbio
0.70
hong kong debut
0.60
drug development
0.50
ai-related stocks
0.40
§ 07
Topic connections
Interactive graph Network visualization showing 2 related topics
View Full Graph Person Organization Location Event|Click node to navigate|Edge numbers = shared articles